NASDAQ:TYMETyme Technologies Stock Price, Forecast & News

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TYME shares have increased by 43.8% and is now trading at $1.51. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tyme Technologies.

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tyme Technologies.

Tyme Technologies Inc (NASDAQ:TYME) released its quarterly earnings results on Wednesday, May, 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.07) by $0.03. View Tyme Technologies' earnings history.

1 brokers have issued 1 year target prices for Tyme Technologies' stock. Their forecasts range from $9.50 to $9.50. On average, they expect Tyme Technologies' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 529.1% from the stock's current price. View analysts' price targets for Tyme Technologies.

News coverage about TYME stock has trended positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tyme Technologies earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutTyme Technologies.

Tyme Technologies saw a decline in short interest in May. As of May 15th, there was short interest totaling 4,740,000 shares, a decline of 7.1% from the April 30th total of 5,100,000 shares. Based on an average daily volume of 382,400 shares, the short-interest ratio is currently 12.4 days. Currently, 8.8% of the company's shares are short sold. View Tyme Technologies' Current Options Chain.

Some companies that are related to Tyme Technologies include Homology Medicines (FIXX), Morphic (MORF), Provention Bio (PRVB), Kadmon (KDMN), Akero Therapeutics (AKRO), G1 Therapeutics (GTHX), Molecular Templates (MTEM), Retrophin (RTRX), Collegium Pharmaceutical (COLL), Arcturus Therapeutics (ARCT), Eagle Pharmaceuticals (EGRX), ZIOPHARM Oncology (ZIOP), Assembly Biosciences (ASMB), Sinovac Biotech (SVA) and INDIVIOR PLC/S (INVVY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Bausch Health Companies (BHC), OpGen (OPGN), Karyopharm Therapeutics (KPTI), Canopy Growth (CGC), NVIDIA (NVDA), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Zynerba Pharmaceuticals (ZYNE) and AcelRx Pharmaceuticals (ACRX).

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Tyme Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (3.27%), State Street Corp (1.15%), Geode Capital Management LLC (0.64%), Nuveen Asset Management LLC (0.20%), Morgan Stanley (0.12%) and Perkins Capital Management Inc. (0.10%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Douglas A Michels, Michael Demurjian, Michele Ilene Korfin and Steve Hoffman. View institutional ownership trends for Tyme Technologies.

TYME stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Wells Fargo & Company MN, Perkins Capital Management Inc., and UBS Group AG. View insider buying and selling activity for Tyme Technologies.

TYME stock was purchased by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Geode Capital Management LLC, Nuveen Asset Management LLC, State Street Corp, and Advisor Group Holdings Inc.. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, Michele Ilene Korfin, and Steve Hoffman. View insider buying and selling activity for Tyme Technologies.

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TYME stock can currently be purchased for approximately $1.51.

Tyme Technologies has a market capitalization of $185.49 million. The company earns $-22,000,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.

The official website for Tyme Technologies is www.tymeinc.com.

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]